Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US0727303028
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BMYGS5
BAYRY
Bayer Aktiengesellschaft
GICS: - · SECTOR: Healthcare · SUB-SECTOR: Drug Manufacturers—General
NAME
Bayer Aktiengesellschaft
ISIN
US0727303028
TICKER
BAYRY
MIC
XOTC
REUTERS
BAYRY.PK
BLOOMBERG
BAYRY US
So., 26.04.2026       Bayer
DE000BAY0017

Das Instrument BAYN DE000BAY0017 BAYER AG NA O.N. EQUITY wird ex Dividende/Zinsen gehandelt am 27.04.2026 The instrument BAYN DE000BAY0017 BAYER AG NA O.N. EQUITY has its ex-dividend/interest day on 27.04.2026...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Bayer
DE000BAY0017

Das Instrument BAYN DE000BAY0017 BAYER AG NA O.N. EQUITY wird cum Dividende/Zinsen gehandelt am 24.04.2026 und ex Dividende/Zinsen am 27.04.2026 The instrument BAYN DE000BAY0017 BAYER AG NA O.N. EQUITY has its pre-dividend/interest day on 24.04.2026 and its ex-dividend/interest day on 27.04.2026...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Bayer
DE000BAY0017

Bayer Canada is proud to support the Simon Fraser University (SFU) School of Medicine - the first medical school in Western Canada in nearly 60 years. The new school is dedicated to help improve primary care and the critical shortage of family doctors in British Columbia, where approximately 800,000 residents lack access to a primary care physicia...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 31.03.2026       Bayer
DE000BAY0017

Bayer today announced a leadership change within its Pharmaceuticals’ Worldwide Markets organization to accelerate the strong performance and growth of its key pharmaceutical products in the U.S. Effective May 1, 2026, Nelson Ambrogio, currently President of Bayer’s global Radiology business, will be appointed President of Bayer U.S. Pharmaceuti...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Bayer
DE000BAY0017

Bayer Crop Science Canada launches Advancing Better Canola (ABCs), an industry-wide initiative to challenge and redefine how it thinks about canola innovation in support of Canadian farmers. Throughout 2026, the Bayer ABCs will drive dialogue, collaboration, and advocacy, while integrating genetics, agronomy, crop protection, and digital tools to...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Bayer
DE000BAY0017

One A Day®, the multivitamin and supplement brand from Bayer backed by more than 80 years of nutritional science, today announced a partnership with Grammy Award winning recording artist, actor and philanthropist Ludacris. The collaboration brings together two names with a shared commitment to simplicity, consistency, and staying power—demonstrati...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Bayer
DE000BAY0017

Bayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship, students entering post-secondary education in agriculture, food science or culinary arts are eligible for one of 12 scholarships valued at $5000 (CAD), with preference given to two ap...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Bayer
DE000BAY0017

The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD) — has met its primary endpoint.1 The results demonstrated a statistically significant improvement versus placebo in the primary e...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mi., 04.03.2026       Bayer
US0727303028

Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. This updated clearance expan...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Fr., 27.02.2026       Bayer
DE000BAY0017

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC)....
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 26.02.2026       Bayer
DE000BAY0017

Final results from the pivotal investigational Phase III PEACE-3 trial demonstrate that first-line treatment with XOFIGO® (radium-223 dichloride) in combination with enzalutamide, an androgen receptor pathway inhibitor (ARPI), resulted in a significant overall survival (OS) benefit, reducing the risk of death by 24% versus enzalutamide alone (haza...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       Bayer
DE000BAY0017

Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of New York. The suit follows J&J’s refusal to cease and desist its promotion of a scientifically flawed real-world evidence analysis that misinforms healthcare providers a...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       Bayer
DE000BAY0017

Leverkusen / St. Louis, February 17, 2026: Class settlement and the U.S. Supreme Court case are independently necessary and mutually reinforcing elements in multi-pronged strategy to significantly contain the litigation Funding of the class totals up to 7.25 billion U.S. dollars; Monsanto will make declining capped annual payments for up to 21 y......
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       Bayer
DE000BAY0017

Leverkusen / St. Louis, 17. Februar 2026: Sammelvergleich und Fall beim US Supreme Court sind Teile der mehrgleisigen Strategie, um Rechtsstreitigkeiten signifikant einzudämmen – beide Elemente sind jeweils notwendig und verstärken sich gegenseitig Zahlungen für den Sammelvergleich umfassen maximal 7,25 Milliarden US-Dollar über bis zu 21 Jahre; ......
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 12.02.2026       Bayer
DE000BAY0017

This American Heart Month, Bayer® Aspirin continues its mission to help people uncover the heart health risk factors they may not see with the launch of the Heart to Heart Bistro presented by Bayer® Aspirin. Created in partnership with Celebrity Chef, Jeff Mauro, the immersive dark dining experience invites Americans to confront one of the most da...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 05.02.2026       Bayer
DE000BAY0017

Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared to placebo, both in combination with antiplatelet therapy. Asundexian significantly reduced ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p<...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 29.01.2026       Bayer
DE000BAY0017

Today Bayer announced it has teamed up with former professional quarterback, Tony Romo, on ‘Highlights REAL,’ a campaign celebrating everyday moments. Tony is joined by his father Ramiro, who has personally faced prostate cancer, to provide play-by-play commentary, not on football, but of advanced prostate cancer patients and their caregivers, fos...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 27.01.2026       Bayer
DE000BAY0017

Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada’s leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located in Winnipeg, Manitoba, the facility will house seed development work for canola, camelina and winter canola, focusing on trait integration, yield tri...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 27.01.2026       Bayer
DE000BAY0017

Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two late-breaking sessions at the upcoming American Stroke Association’s International Stroke Conference (ISC) 2026. The conference will be held February 4-6 in New Orleans, Lou...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 20.01.2026       Bayer
DE000BAY0017

Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug (IND) application. The agreement spans across all indications currently pursued by Bayer, initially focusing on cardio...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 16.01.2026       Bayer
DE000BAY0017

The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circuit courts on the application of federal preemption, a cross-cutting issue in the Roundup™ litigation. The company expects a decision on the merits du...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 13.01.2026       Bayer
DE000BAY0017

On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercia...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 13.01.2026       Bayer
DE000BAY0017

Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn’t Stop for a Hot Flash’ campaign, which speaks to women with moderate to severe hot flashes due to menopause. The campaign encourages women to have an open and honest conversation with their healthcare provider about their hot flash e...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Bayer
DE000BAY0017

Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for systemic amyloidosis, today announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 (124-Iodine-evuzamitide) and AT-...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 08.01.2026       Bayer
DE000BAY0017

Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to advance a heart-targeted small interfering RNA (siRNA) therapy. The companies will collaborate to develop a siRNA-based treatment for a form of dila...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 05.01.2026       Bayer
DE000BAY0017

Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s Pharmaceuticals Division, will present updates on the company’s pharmaceutical growth strategy and pipeline advancements across its p...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 16.12.2025       Bayer
DE000BAY0017

Bayer Crop Science Canada is excited to announce the launch of Sivanto® Energy, a groundbreaking foliar insecticide designed to deliver swift, reliable pest control with extended protection. Formulated to deliver two highly effective modes of action, Sivanto Energy combines the strengths of deltamethrin and flupyradifurone to provide unparalleled...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 04.12.2025       Bayer
DE000BAY0017

Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a rando...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mi., 03.12.2025       Bayer
DE000BAY0017

Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhance...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 02.12.2025       Bayer
DE000BAY0017

Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, d...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 02.12.2025       Bayer
DE000BAY0017

Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverGol Rise brings enhanced disease control to tough pathogens, like ascochyta, while also keeping the user ease of use top of mind. This press release features multimedia. View the full re...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 01.12.2025       Bayer
DE000BAY0017

Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent presentations to include single-dose vials in addition to the previously cleared Imaging Bulk Package (IBP) presentations for Ultravist® (iopromide),...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
So., 23.11.2025       Bayer
DE000BAY0017

Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary efficacy and safety endpoints. Asundexian 50 mg once daily significantly reduced the risk of ischemic stroke compared to placebo, both in combination with ant...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
So., 23.11.2025       Bayer
DE000BAY0017

Leverkusen / Berlin, 23. November 2025 – Bayer hat heute positive Topline-Ergebnisse aus der globalen Phase-III-Studie OCEANIC-STROKE mit dem Prüfpräparat Asundexian, einem einmal täglich oral verabreichten FXIa-Hemmer, bekannt gegeben. Die Studie erreichte ihre primären Wirksamkeits- und Sicherheitsendpunkte. Asundexian, 50 mg einmal täglich, redu......
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 20.11.2025       Bayer
DE000BAY0017

Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved HYRNUO® (sevabertinib), an oral, reversible, tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activat...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 10.11.2025       Bayer
DE000BAY0017

Today, on World Science Day, Bayer is proud to launch its “Science Delivers” campaign, a nationwide initiative celebrating how science delivers answers, hope, and progress for all Americans—every day, in the moments that matter most. From the medicine that keeps us healthy to the technology that connects and helps feed us, to the innovations tha...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Bayer
DE000BAY0017

The Supervisory Board of Bayer AG has appointed Dr. Judith Hartmann to the company’s Board of Management, effective March 1, 2026. She will succeed Wolfgang Nickl as the company’s Chief Financial Officer (CFO) on June 1, 2026, following his planned retirement at the end of May 2026. Dr. Hartmann is currently an Operating Partner at Sandbrook Capit...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Bayer
DE000BAY0017

Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from baseline over six months by 25% compared to placebo in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) who were receiving standard of c...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Fr., 24.10.2025       Bayer
DE000BAY0017

Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause.1 Inhibition of Substance P and Neurokin...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 21.10.2025       Bayer
DE000BAY0017

Bayer will present methods and baseline characteristic data from the global Phase III OCEANIC-STROKE study with the investigational agent asundexian, in a late-breaking presentation at the upcoming 17th World Stroke Congress, being held in Barcelona, Spain from October 22 – 24. Bayer presentations on OCEANIC-STROKE include: Factor XIa (FXIa)...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 07.10.2025       Bayer
DE000BAY0017

Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm in the United States. This recognition places Cornfed Farms as one of 16 farms around the globe, highlighted by Bayer as committed to advancing regenera...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 07.10.2025       Bayer
DE000BAY0017

One A Day®, the multivitamin and supplement brand by Bayer rooted in 80+ years of nutritional science, today announced a bold new brand identity and positioning designed to better connect with today’s consumers and their evolving health needs. The rebrand, rolling out nationwide this fall, introduces a refreshed visual identity, packaging, and pur...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Di., 07.10.2025       Bayer
DE000BAY0017

Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced positive 36-month data from exPDite, a Phase I clinical trial of bemdaneprocel, an investigational cell therapy for the treatment of Parkinson's disease (PD). The data were presented on October 6th at th...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 29.09.2025       Bayer
DE000BAY0017

The Consumer Health division of Bayer has selected Interpublic Group (NYSE: IPG) as the global agency partner for all creative, production and media, responsible for marketing activities for some of the most trusted and well-known brands in self-care. The selection of an integrated agency across brands and regions represents a new era in how Bay...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 25.09.2025       Bayer
DE000BAY0017

Bayer Canada is pleased to announce a new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL® 30 mg tablets1 in Canada. This strategic collaboration took effect on September 3, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250925537941/en/From Left to...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Do., 25.09.2025       Bayer
DE000BAY0017

Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific Meeting in Minneapolis, Minnesota, September 26-29, 2025. In July 2025, the U.S. Food and Drug Administration (FDA) approved a new indication for KERENDIA...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 22.09.2025       Bayer
DE000BAY0017

Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for PD. At the same time, first European participants have been randomized in REGENERATE-PD, a Phase II...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 15.09.2025       Bayer
DE000BAY0017

Bayer today announced a milestone in its Take Care, Now campaign with country superstar and five-time Entertainer of the Year, Luke Bryan, and Feeding America®, the nation’s largest hunger-relief organization. The effort builds on last year’s success to address both food insecurity and “hidden hunger” – nutrient gaps that can impact long-term heal...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Bayer
DE000BAY0017

Bayer today announced that a New Drug Application (NDA) for its investigational contrast agent gadoquatrane has been accepted for review by the U.S. Food and Drug Administration (FDA). The NDA for gadoquatrane has been filed for contrast-enhanced magnetic resonance imaging of the central nervous system (CNS) and other body regions in adults and pe...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink
Mo., 18.08.2025       Bayer
DE000BAY0017

Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts that remain on appeal. The Sky Valley Education Center cases involve allegations of injuries due to exposure to polychlorinated biphenyls (PCBs) at the sc...
Zur Nachricht
Bayer
Charts & Research Termsheets Terminal
Permalink